nascentbiotech.com
Nascent Biotech Receives Clearance from FDA to Begin Phase I Human Trials in Brain Cancer - Nascent Biotech
Vero Beach, FL December 10, 2018 – Nascent Biotech, Inc. (OTC: NBIO) Received US Food and Drug Administration (FDA) Clearance to begin Phase 1 Clinical Trials effective December 7th, 2018. Nascent CEO Sean Carrick stated, “On Friday December 7, 2018, Nascent Biotech received a letter from the FDA moving the Company’s IND filing from Full …